See more : Hunter Douglas N.V. (0LN5.L) Income Statement Analysis – Financial Results
Complete financial analysis of Malin Corporation plc (MLC.IR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Malin Corporation plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BRONCO BILLY Co., LTD. (3091.T) Income Statement Analysis – Financial Results
- Siemens Aktiengesellschaft (SIEGY) Income Statement Analysis – Financial Results
- PT Sreeya Sewu Indonesia Tbk (SIPD.JK) Income Statement Analysis – Financial Results
- Flat Capital AB (publ) (FLAT-B.ST) Income Statement Analysis – Financial Results
- Cytokinetics, Incorporated (CYTK) Income Statement Analysis – Financial Results
Malin Corporation plc (MLC.IR)
About Malin Corporation plc
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 41.00M | 34.90M | 38.00M | 41.90M | 42.10M | 22.90M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 30.80M | 27.40M | 33.90M | 30.80M | 30.60M | 19.30M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 10.20M | 7.50M | 4.10M | 11.10M | 11.50M | 3.60M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 24.88% | 21.49% | 10.79% | 26.49% | 27.32% | 15.72% |
| Research & Development | 0.00 | 0.00 | 0.00 | 6.60M | 2.70M | 3.90M | 11.50M | 5.10M | 2.70M |
| General & Administrative | 3.90M | 200.00K | 2.60M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 19.80M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 11.00M | 16.30M | 16.90M | 26.70M | 33.70M | 0.00 |
| SG&A | 3.90M | 200.00K | 2.60M | 11.00M | 16.30M | 16.90M | 26.70M | 33.70M | 19.80M |
| Other Expenses | 600.00K | 500.00K | 0.00 | 1.50M | 2.50M | 6.60M | 18.20M | 19.20M | 8.10M |
| Operating Expenses | 4.50M | 700.00K | 2.60M | 19.10M | 21.50M | 27.40M | 56.40M | 58.00M | 30.60M |
| Cost & Expenses | 4.50M | 700.00K | 2.60M | 49.90M | 48.90M | 61.30M | 87.20M | 88.60M | 49.90M |
| Interest Income | 1.00K | 200.00 | 1.20K | 300.00K | 100.00K | 0.00 | 500.00K | 500.00K | 0.00 |
| Interest Expense | 0.00 | 200.00K | 1.20M | 3.40M | 3.30M | 2.90M | 3.00M | 2.00M | 800.00K |
| Depreciation & Amortization | 100.00K | 100.00K | 3.70M | 5.40M | 5.10M | 5.20M | 5.40M | 5.00M | 2.60M |
| EBITDA | -3.80M | 13.90M | 1.60M | 2.00M | -5.40M | -25.00M | -39.90M | -41.50M | -27.60M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 4.88% | -15.47% | -65.79% | -213.37% | -185.27% | -120.52% |
| Operating Income | -4.50M | 13.60M | -1.40M | -3.40M | -14.00M | -25.60M | -62.70M | -56.20M | -45.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -8.29% | -40.11% | -67.37% | -149.64% | -133.49% | -198.69% |
| Total Other Income/Expenses | 4.50M | 16.10M | -1.20M | 97.70M | 7.50M | -25.10M | -44.70M | -30.10M | -7.80M |
| Income Before Tax | 0.00 | 12.30M | -3.80M | 91.00M | -6.50M | -50.70M | -107.40M | -86.30M | -49.80M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 221.95% | -18.62% | -133.42% | -256.32% | -204.99% | -217.47% |
| Income Tax Expense | 0.00 | -600.00K | -3.30M | 3.70M | -1.30M | -900.00K | -1.20M | 300.00K | -200.00K |
| Net Income | 0.00 | 12.90M | -500.00K | 87.70M | -5.20M | -46.30M | -98.80M | -83.50M | -44.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 213.90% | -14.90% | -121.84% | -235.80% | -198.34% | -196.07% |
| EPS | 0.00 | 0.38 | -0.01 | 1.90 | -0.11 | -1.01 | -2.36 | -2.12 | -1.63 |
| EPS Diluted | 0.00 | 0.38 | -0.01 | 1.90 | -0.11 | -1.01 | -2.36 | -2.12 | -1.63 |
| Weighted Avg Shares Out | 22.30M | 34.30M | 44.60M | 45.90M | 45.90M | 45.70M | 41.80M | 39.40M | 27.50M |
| Weighted Avg Shares Out (Dil) | 22.30M | 34.30M | 44.60M | 46.30M | 45.90M | 45.70M | 41.80M | 39.40M | 27.50M |
Source: https://incomestatements.info
Category: Stock Reports